PEPFAR and The Global Fund Invest in Gilead's Lenacapavir to Expand HIV Prevention Access
Gilead Sciences, Inc. has announced a significant investment from the U.S. State Department's President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to expand access to its HIV prevention drug, lenacapavir. This investment aims to provide the drug to an additional one million people over the next three years, focusing on high-incidence, resource-limited countries. Lenacapavir, a twice-yearly injectable, is the first HIV prevention therapy to be distributed in sub-Saharan Africa in the same year it was approved in the United States. Gilead is working with PEPFAR and The Global Fund to ensure the drug reaches those in greatest need, providing it at no profit in countries with urgent demand. The company plans a large-scale generic rollout by 2027, with voluntary licensing agreements in place with six generic manufacturers. 
